HACKENSACK, N.J.--(BUSINESS WIRE)--Andre Goy, M.D., M.S., Chairman and Director of John Theurer Cancer Center and Chief of the Lymphoma Program, announced today that ibrutinib, to be marketed as Imbruvica, has been approved by the FDA based on clinical studies conducted at John Theurer Cancer Center in previously treated mantle cell lymphoma patients. Imbruvica becomes the first-in-class of drugs targeting the B-cell receptor pathway. Approval of Imbruvica was granted under breakthrough therapy designation based on the strong positive results demonstrated in the clinical trial.
Help employers find you! Check out all the jobs and post your resume.
